News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Delayed Nasdaq Other stock markets 12:53:37 2024-04-26 pm EDT			5-day change	1st Jan Change
2.43 ^USD	-1.62%		+8.00%	+4.30%

Apr. 04	Transcript : VYNE Therapeutics Inc. - Special Call
Feb. 29	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : VYNE Therapeutics Inc. - Special Call	Apr. 04
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 19	AQ
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	Feb. 29	MT
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	Feb. 29	AQ
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	Feb. 27	AQ
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 21	AQ
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	AQ
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	Jan. 10	CI
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	Jan. 03	CI
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	Jan. 03	AQ
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	Nov. 13	MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	AQ
Transcript : VYNE Therapeutics Inc. - Special Call	Nov. 09
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023	Nov. 07	AQ
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million	Nov. 01	AQ
VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors	Oct. 31	CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	23-10-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Summary

Filters